Epcoritamab and R-CHOP for Non-Hodgkin's Lymphoma

Phase-Based Progress Estimates
Victoria Hospital /ID# 226885, London, CanadaNon-Hodgkin's LymphomaRituximab - Drug
18 - 79
All Sexes
What conditions do you have?

Study Summary

This trial will study an investigational drug, epcoritamab, to assess its effect on disease activity in people with a form of cancer called diffuse large B-cell lymphoma (DLBCL). 900 participants will be enrolled in 315 sites globally.

Eligible Conditions
  • Non-Hodgkin's Lymphoma

Treatment Effectiveness

Effectiveness Progress

2 of 3
This is further along than 85% of similar trials

Study Objectives

2 Primary · 5 Secondary · Reporting Duration: Up to Approximately 76 Months

Week 28
Percentage of Participants with Complete Remission (CR)
Month 43
Number of Participants with Progression-Free Survival (PFS)
Month 46
Number of Participants with Event-free survival (EFS)
Number of Participants with PFS
Number of Participants with Progression-Free Survival (PFS) with an International Prognostic Index (IPI) of 3-5
Percentage of Participants with Minimal Residual Disease (MRD) Negativity
Month 76
Overall survival (OS)

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Trial Design

2 Treatment Groups

Epcoritamab and R-CHOP
1 of 2
R-CHOP and Rituximab
1 of 2

Experimental Treatment

900 Total Participants · 2 Treatment Groups

Primary Treatment: Epcoritamab and R-CHOP · No Placebo Group · Phase 3

Epcoritamab and R-CHOPExperimental Group · 6 Interventions: Rituximab, Epcoritamab, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone · Intervention Types: Drug, Drug, Drug, Drug, Drug, Drug
R-CHOP and RituximabExperimental Group · 5 Interventions: Rituximab, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone · Intervention Types: Drug, Drug, Drug, Drug, Drug
First Studied
Drug Approval Stage
How many patients have taken this drug
Completed Phase 4
Completed Phase 3
Completed Phase 4
Completed Phase 3
Completed Phase 4

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to approximately 76 months

Who is running the clinical trial?

AbbVieLead Sponsor
852 Previous Clinical Trials
472,751 Total Patients Enrolled
GenmabIndustry Sponsor
46 Previous Clinical Trials
8,276 Total Patients Enrolled
ABBVIE INC.Study DirectorAbbVie
313 Previous Clinical Trials
120,134 Total Patients Enrolled

Eligibility Criteria

Age 18 - 79 · All Participants · 7 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You are planning to receive six cycles of a standard chemotherapy treatment called R-CHOP.

Frequently Asked Questions

Does this research involve participants that are 20 or older?

"The age range that is able to enroll in this clinical trial, as specified by the eligibility criteria, is 18 to 79 years old." - Anonymous Online Contributor

Unverified Answer

How does the safety profile of R-CHOP and Rituximab compare to other similar treatments?

"The safety of R-CHOP and Rituximab was given a score of 3. This is based on the fact that this is a Phase 3 trial - meaning that there is efficacy data as well as multiple rounds of data in support of safety." - Anonymous Online Contributor

Unverified Answer

Is this research still enrolling new participants?

"The clinical trial in question is no longer looking for participants, as indicated by the fact that it was last updated over 8 months ago. However, there are 1807 other studies that are still recruiting patients." - Anonymous Online Contributor

Unverified Answer

Who meets the qualifications to participate in this clinical trial?

"This clinical trial is looking for 900 participants that have diffuse large b-cell lymphoma (dlbcl). The patients must be 18-79 years old and meet the following criteria: They must be planned to receive treatment with 6 cycles of standard rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone (R-CHOP) per investigator determination., DLBCL, Not Otherwise Specified (NOS)., High grade B-cell lymphoma with MYC and BCL-2 and/or BCL-6 rearrangement with" - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.